Dr Reddy's launches Posaconazole Tablets in US market

21 Apr 2022 , 10:57 AM

Dr. Reddy’s Laboratories Ltd. has announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, the therapeutic generic equivalent to NOXAFIL (posaconazole) Delayed-Release Tablets, 100 mg approved by the U.S. Food and Drug Administration (USFDA).

The NOXAFIL brand and generic had U.S. sales of approximately $140.8 million MAT for the most recent twelve months ending in February 2022 according to IQVIA*.

Dr. Reddy’s Posaconazole Delayed-Release Tablets are available in 100 mg strength in bottle count sizes of 60, said company.

At around 11:00 AM, Dr Reddys Laboratories was trading at Rs4,325.30 apiece up by Rs33.85 or 0.79% on the BSE.